Orchestra BioMed Inc.

OBIO | NASDAQ

Price Alert Chart Builder DCF Calculator

$6.25

+$0.17 (+2.80%)

At close: Sep 21, 2026, 4:00 PM ET

$6.35

+$0.10 (+1.60%)

Pre-market: Sep 22, 2026, 7:47 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.80%

(1D)

Rating

Updated: Aug 11, 2026

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $374.25M

1D Range

5.89 6.30

52W Range

2.20 6.30

Valuation (TTM)

PE -4.81

PB 19.37

EV/EBITDA -4.65

Valuation (NTM)

Forward PE N/A

Forward PEG 9.23

Price Target $11

Cash Flow

FCF Yield -15.8%

SBC Adj. FCF Yield -18.8%

SBC Impact -18.8%

Margins

Gross Margin 99.3%

Operating Margin -181.4%

FCF Margin -184.8%

Growth (CAGR)

Revenue 3Y | 5Y 94.5% | 148.4%

Dil EPS 3Y | 5Y 8.6% | -6.9%

FCF 3Y | 5Y -13.2% | -20.1%

Returns

ROA -51.0%

ROE -125.9%

ROIC -56.3%

Financial Health

Net Cash

$108.64M

Current Ratio 8.26

Interest Coverage -27.63

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypert...

Sector Healthcare

Industry Biotechnology

Employees 86

IPO Date Aug 3, 2020

Website orchestrabiomed.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 9, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$10

Upside

+60.00%

Buy (6)

Hold (0)

Sell (0)

Analyst Details ➞